Director/PDMR Shareholding
Published: Jun 02, 2026 03:42:42 PM
Sequence No.: 37
ISIN: US4312882081
Hikma Pharmaceuticals PLC – LTIP and EIP Vesting
LONDON, 2 June 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (Nasdaq Dubai: HIK) (“Hikma”) (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility (“PDMRs”) have received shares as a result of the vesting of their conditional share awards which were granted on 30 May 2023 under the 2023 Long-Term Incentive Plan (“LTIP”) and 2014 Executive Incentive Plan (“EIP”) Element C.
Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities
Said Darwazah
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
| a) |
Name |
Said Darwazah |
|
| 2 |
Reason for the notification |
||
| a) |
Position/status |
Chief Executive Officer |
|
| b) |
Initial notification /Amendment |
Initial notification |
|
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
| a) |
Name |
Hikma Pharmaceuticals PLC |
|
| b) |
LEI |
549300BNS685UXH4JI75 |
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (“Shares”) ID Code: GB00B0LCW083 |
|
| b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| Nil |
LTIP Award: 91,812 |
||
| Nil |
EIP Award, Element C: 19,761 |
||
| d) |
Aggregated information |
Price(s): nil Volume(s): 111,573 |
|
| e) |
Date of the transaction |
1 June 2026 |
|
| f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Mazen Darwazah
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
| a) |
Name |
Mazen Darwazah |
|
| 2 |
Reason for the notification |
||
| a) |
Position/status |
Executive Vice Chairman and Deputy CEO, MENA |
|
| b) |
Initial notification /Amendment |
Initial notification |
|
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
| a) |
Name |
Hikma Pharmaceuticals PLC |
|
| b) |
LEI |
549300BNS685UXH4JI75 |
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (“Shares”) ID Code: GB00B0LCW083 |
|
| b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| Nil |
LTIP Award: 72,763 |
||
| Nil |
EIP Award, Element C: 20,650 |
||
| d) |
Aggregated information |
Price(s): nil Volume(s): 93,413 |
|
| e) |
Date of the transaction |
1 June 2026 |
|
| f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Khalid Nabilsi
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
| a) |
Name |
Khalid Nabilsi |
|
| 2 |
Reason for the notification |
||
| a) |
Position/status |
Deputy CEO, North America and Europe |
|
| b) |
Initial notification /Amendment |
Initial notification |
|
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
| a) |
Name |
Hikma Pharmaceuticals PLC |
|
| b) |
LEI |
549300BNS685UXH4JI75 |
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (“Shares”) ID Code: GB00B0LCW083 |
|
| b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| Nil |
LTIP Award: 51,650 |
||
| Nil |
EIP Award, Element C: 22,209 |
||
| d) |
Aggregated information |
Price(s): nil Volume(s): 73,859 |
|
| e) |
Date of the transaction |
1 June 2026 |
|
| f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Bassam Kanaan
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
| a) |
Name |
Bassam Kanaan |
|
| 2 |
Reason for the notification |
||
| a) |
Position/status |
PDMR |
|
| b) |
Initial notification /Amendment |
Initial notification |
|
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
| a) |
Name |
Hikma Pharmaceuticals PLC |
|
| b) |
LEI |
549300BNS685UXH4JI75 |
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (“Shares”) ID Code: GB00B0LCW083 |
|
| b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| Nil |
LTIP Award: 52,640 |
||
| Nil |
EIP Award, Element C: 20,982 |
||
| d) |
Aggregated information |
Price(s): nil Volume(s): 73,622 |
|
| e) |
Date of the transaction |
1 June 2026 |
|
| f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Hussein Arkhagha
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
| a) |
Name |
Hussein Arkhagha |
|
| 2 |
Reason for the notification |
||
| a) |
Position/status |
PDMR |
|
| b) |
Initial notification /Amendment |
Initial notification |
|
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
| a) |
Name |
Hikma Pharmaceuticals PLC |
|
| b) |
LEI |
549300BNS685UXH4JI75 |
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (“Shares”) ID Code: GB00B0LCW083 |
|
| b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. |
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| Nil |
LTIP Award: 28,631 |
||
| Nil |
EIP Award, Element C: 12,406 |
||
| d) |
Aggregated information |
Price(s): nil Volume(s): 41,037 |
|
| e) |
Date of the transaction |
1 June 2026 |
|
| f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Susan Ringdal
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
| a) |
Name |
Susan Ringdal |
|
| 2 |
Reason for the notification |
||
| a) |
Position/status |
PDMR |
|
| b) |
Initial notification /Amendment |
Initial notification |
|
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
| a) |
Name |
Hikma Pharmaceuticals PLC |
|
| b) |
LEI |
549300BNS685UXH4JI75 |
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (“Shares”) ID Code: GB00B0LCW083 |
|
| b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the LTIP and EIP. |
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| Nil |
LTIP Award: 26,558 |
||
| Nil |
EIP Award, Element C: 11,664 |
||
| d) |
Aggregated information |
Price(s): nil Volume(s): 38,222 |
|
| e) |
Date of the transaction |
1 June 2026 |
|
| f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (“Shares”) ID Code: GB00B0LCW083 |
|
| b) |
Nature of the transaction |
All shares sold following the vesting of conditional awards under the LTIP and EIP. |
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| £14.49 |
LTIP Award: 26,558 |
||
| £14.49 |
EIP Award, Element C: 11,664 |
||
| d) |
Aggregated information |
Price(s): £14.49 Volume(s): 38,222 Total(s): £553,748.83 |
|
| e) |
Date of the transaction |
1 June 2026 |
|
| f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Helen Middlemist
Group Company Secretary
+44 (0)20 7399 2760
Comments